FDA grants breakthrough status to Augurex’s SPINEstat test to advance early axSpA diagnosis

GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy

The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio

FDA approves Bayer’s Lynkuet as first hormone-free therapy for menopausal hot flashes

This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms

Elixion Biotech takes quantum-informed R&D route for next-gen precision medicines

Orion secures license to Abzena’s next-generation cancer antibody

The antibody was designed and developed at Abzena’s Cambridge, UK,

Sanofi India appoints Deepak Arora as MD

Arora brings over 30 years of experience in the pharmaceutical and healthcare industry

Novartis to acquire Avidity Biosciences for $12 billion

The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company

GSK acquires rights to prostate-cancer candidate from Syndivia for up to £268 million

Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile

Lilly buys Adverum for its phase 3-stage eye disease gene therapy

Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose

Syngene International expands capabilities with new bioconjugation suite in Bengaluru

Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services